Immunoglobulin News and Research

RSS

CSL partners with NIH to study Cytomegalovirus, a common cause of abnormalities in newborns

CSL Limited announced today that it is partnering with the world’s largest health research agency, the US National Institutes of Health (NIH), to study a potential new treatment for the prevention of congenital CMV infection, one of the most common known causes of congenital (i.e., present at birth) abnormalities in the developed world.

7 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Laminar air flow therapy via novel device could be beneficial for asthmatics: Study

A new device that offers drug-free bedside filtered air flow can significantly reduce patients' symptoms such as wheezing and tight chests in asthmatics. The temperature controlled laminar airflow treatment, called Protexo, filters out airborne triggers such as dust particles and mites, pet hairs and powders that cause irritation and inflammation of the lungs.

27 Nov 2011

Nocturnal temperature controlled laminar airflow treatment for atopic asthma

A simple device that filters out airborne asthma triggers during sleep can ease persistent symptoms of the condition during the day and improve quality of life, suggests research published online in Thorax.

24 Nov 2011

$GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation$

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

GE Healthcare, the healthcare business of GE and Neste Jacobs, a leading global expert in plasma fractionation plant engineering design and construction, announced today that the companies have formed a strategic alliance to assist countries worldwide to become self-sufficient in the manufacture of blood plasma products.

21 Nov 2011

Possible link between norovirus and food allergies

Researchers at the Medical College of Wisconsin have found a possible link between norovirus, a virus that causes "stomach flu" in humans, and food allergies.

15 Nov 2011

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Baxter International Inc. today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI).

From Baxter International Inc. 7 Nov 2011

Octapharma receives FDA approval for octagam to treat disorders of immune system

The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam, the Octapharma USA product used to treat disorders of the immune system.

5 Nov 2011

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

29 Oct 2011

HDM and SCT increase overall survival for patients with AL amyloidosis

A team of researchers led by Boston University School of Medicine (BUSM), has found treatment of selected immunoglobulin light chain (AL) amyloidosis patients with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) resulted in a high organ response rate and increased overall survival (OS), even for those patients who did not achieve a hematologic complete response.

27 Oct 2011

Children have fewer components that strengthen their immune defense than adults do

Children have fewer components that strengthen their immune defense than adults do. This is shown in a mapping of children's saliva that was carried out at Malmö University in Sweden. The study may have found an explanation for children's inability to fend off infections.

27 Oct 2011

Study: pGJA-P/VAX vaccine shows promise against dental caries

In a report on a preclinical investigation titled "Flagellin Enhances Saliva IgA Response and Protection of Anti-caries DNA Vaccine," lead author Wei Shi, Wuhan Institute of Virology, Chinese Academy of Sciences, and his team of researchers demonstrate that anti-caries DNA vaccines, including pGJA-P/VAX, are promising for preventing dental caries. However, challenges remain because of the low immunogenicity of DNA vaccines.

27 Oct 2011

VTT to develop next-generation vaccines against allergy

VTT holds patents on gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.

22 Oct 2011

Subjects with borderline elevated IgE levels less likely to develop glioma

A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.

19 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

Halozyme commences HTI-501 clinical trial for cellulite in women

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

28 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Scientists successfully disrupt function of MYC cancer gene

Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself.

12 Sep 2011

Immunoglobulin News and Research

CSL partners with NIH to study Cytomegalovirus, a common cause of abnormalities in newborns

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Laminar air flow therapy via novel device could be beneficial for asthmatics: Study

Nocturnal temperature controlled laminar airflow treatment for atopic asthma

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

Possible link between norovirus and food allergies

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Octapharma receives FDA approval for octagam to treat disorders of immune system

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

HDM and SCT increase overall survival for patients with AL amyloidosis

Children have fewer components that strengthen their immune defense than adults do

Study: pGJA-P/VAX vaccine shows promise against dental caries

VTT to develop next-generation vaccines against allergy

Subjects with borderline elevated IgE levels less likely to develop glioma

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Baxter seeks European marketing authorization for HyQ to treat PI

Halozyme commences HTI-501 clinical trial for cellulite in women

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

Scientists successfully disrupt function of MYC cancer gene

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News